Cedar Health Research, a Texas-based clinical trial network focused on underserved patients, and Texas Native Health, a Dallas nonprofit serving American Indian and Alaska Native communities, announced on Wednesday that they have opened a new embedded Cedar Health Research site within Texas Native Health.
Established in 2023, the collaborative partnership aims to expand access to clinical research for Native American patients, a population that has historically been underrepresented in clinical trials.
The integrated site allows patients to participate in studies within their trusted care setting, reducing barriers such as travel, limited culturally informed study designs, and longstanding underrepresentation in clinical data.
Initially, the site will support studies addressing conditions disproportionately affecting Native American populations, such as cardiometabolic diseases. Native Americans are 36% more likely than the general US population to have diabetes, and approximately 50% of Native American adults are obese.
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin